CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 9 enrolled
Drug / intervention
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01775774
NCT01775774Phase 1Completed
CompareCT.gov

A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome

Michael A. Matthay·interventional·Posted Jan 25, 2013·Updated Aug 14, 2017

In Brief

A Phase 1 clinical trial evaluating Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells for Acute Respiratory Distress Syndrome. Completed, enrolled 9 participants across 4 sites.

Detailed Summary

This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Respiratory Distress Syndrome
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Massachusetts General Hospital, Stanford University, University of Pittsburgh, University of Minnesota

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 25, 2013
Enrollment StartJul 1, 2013
Primary CompletionFeb 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.4 years ago

Interventions

Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cellsbiological

Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.